Several small-molecule CXCR1/2 inhibitors also presented potent therapeutic efficacy upon combined use with other targeted therapies, chemotherapies, and immunotherapies in various malignancies such as head and neck squamous cell carcinoma, non-small cell lung cancer, prostate cancer, and breast cancer [41, 80–83]. The gene discussed is CXCR1; the disease is prostate cancer.